Zentalis Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M |
| Operating expenses | $152.8M | $258.6M | $299.5M | $227.3M | $216.5M |
| Cash from operations | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M |
| Capital expenditure | $0 | $221,000 | $583,000 | $2.5M | $6.1M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M |
| Share repurchases | $10.0M | $0 | $0 | — | — |
| Impairments | $0 | $3.7M | $0 | $0 | $8.8M |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M |
Shares outstanding 71.2M · Free float 77.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.